Calluna Pharma
Calluna Pharma is a clinical-stage biotech developing first-in-class monoclonal antibodies (CAL101 targeting S100A4 for IPF; CAL103 targeting OxPL for inflammatory diseases) that address upstream drivers of inflammation and fibrosis, serving patients with serious fibrotic and chronic inflammatory conditions.
- Company typePrivate
- Founded2023
- HeadquartersOslo, Norway
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Calluna Pharma does
Calluna Pharma is a clinical-stage biotechnology company headquartered in Oslo, Norway, with an additional presence in Boston, Massachusetts. Formed in 2023 through the merger of Oxitope Pharma and Arxx Therapeutics and financed in January 2024 with a EUR 75 million Series A led by Forbion, the company is developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers — specifically damage-associated molecular pattern (DAMP) proteins and oxidized phospholipids (OxPLs) — to address chronic inflammation and fibrosis at the source rather than modulating downstream mediators.
Its pipeline is anchored by CAL101, a humanized anti-S100A4 monoclonal antibody currently being evaluated in the Phase 2 AURORA study in idiopathic pulmonary fibrosis (IPF) and positioned for additional fibrotic indications such as systemic sclerosis. The company's second program, CAL103, targets oxidized phospholipids for chronic inflammatory and respiratory conditions, including COPD and rheumatoid arthritis, and is being advanced through a co-development partnership with Lilly ExploR&D. The platform is supported by over 30 years of co-founder research, peer-reviewed publications, and regulatory milestones including FDA Orphan Drug Designation for CAL101 in IPF (October 2025).
Calluna is pre-revenue and does not yet commercialize any product. Its value-creation model is the standard clinical-stage biotech playbook: advance candidates through clinical development, secure regulatory designations, and ultimately generate revenue through product sales upon approval or via licensing/royalty agreements such as the existing CAL103 arrangement with Lilly. The company targets approximately 233,000 IPF patients in the US and EU, a market estimated at roughly $3 billion in 2025 and growing toward nearly $7 billion by 2035. Topline Phase 2 data from AURORA (161 patients enrolled across 50+ sites) are expected in Q1 2027.
Calluna Pharma firmographics
Firmographics- Name
- Calluna Pharma
- Legal name
- Calluna Pharma
- Website
- https://callunapharma.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Calluna Pharma is a clinical-stage biotech developing first-in-class monoclonal antibodies (CAL101 targeting S100A4 for IPF; CAL103 targeting OxPL for inflammatory diseases) that address upstream drivers of inflammation and fibrosis, serving patients with serious fibrotic and chronic inflammatory conditions.
- Ownership category
- akta.pro rank
Calluna Pharma industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Calluna Pharma is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices2 records
Markets served
Calluna Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development & Licensing: Calluna Pharma is a pre-revenue clinical-stage biotechnology company. Its primary value creation comes from developing novel therapeutic candidates through clinical trials and out-licensing or commercializing resulting products. Revenue will ultimately derive from product sales upon regulatory approval, with potential milestone payments from partnerships such as the existing CAL103 partnership with Lilly ExploR&D.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Calluna Pharma product offering
Product offeringCore offering
Calluna Pharma is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers (the DAMP protein S100A4 and oxidized phospholipids) to treat chronic inflammatory and fibrotic diseases. Its lead candidate CAL101 is in Phase 2 development for idiopathic pulmonary fibrosis (IPF), while CAL103 is being co-developed with Lilly ExploR&D for chronic inflammatory indications such as COPD and rheumatoid arthritis.
Product overview
Calluna Pharma is a clinical-stage biotechnology company pioneering first-in-class therapeutic antibodies to treat inflammatory and fibrotic diseases. The company's pipeline consists of CAL101 (targeting S100A4 for idiopathic pulmonary fibrosis, currently in Phase 2) and CAL103 (targeting oxidized phospholipids for chronic inflammatory conditions, in preclinical/early development). These antibodies leverage over 30 years of research to target upstream innate immune amplifiers, modulating disease-associated signaling pathways while ensuring a favorable safety profile.
Differentiator
Problem solved
Functional benefit
Products and services
- CAL101
- CAL103
Quantifiable outcome
- Phase 1 study in 57 subjects: favorable safety profile with no Serious Adverse Events across all doses; balanced frequency and types of AEs vs placebo; favorable PK with dose-dependent increases in exposure supporting once monthly dosing; very low anti-drug antibody titers with no impact on PK and safety; complete target coverage at clinically relevant doses
- +2 more outcomes
Companies that use Calluna Pharma
Customer profileSegments2 records
Ideal customer profiles3 records
Calluna Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Calluna Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Medicines Evaluation Unit (MEU), Manchester, UKminorThe Phase 1 first-in-human study of CAL101 was led by Professor Dave Singh at the Medicines Evaluation Unit in Manchester, UK. The randomized, double-blind, placebo-controlled study enrolled 57 subjects to evaluate safety, tolerability, immunogenicity, and pharmacokinetics.
- Lilly ExploR&DcoreCAL103 (targeting oxidized phospholipids) is listed 'In partnership with Lilly ExploR&D' in Calluna Pharma's pipeline, indicating a co-development or licensing partnership for the CAL103 program targeting chronic inflammatory and respiratory conditions.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Calluna Pharma competitors and assessment
Company assessmentDirect peers
- FibroGen: Developed pamrevlumab for IPF through late-stage trials; same lead indication as Calluna and serves as the most relevant cautionary comparable for clinical-stage IPF assets.
- Pliant Therapeutics: Clinical-stage biotech developing integrin-targeting therapies for IPF and fibrotic diseases; bexotegrast is in Phase 2b/3 for IPF, making it the most directly comparable late-stage fibrosis peer to Calluna.
- Avalyn Pharma: Clinical-stage biotech developing inhaled pirfenidone (AP01) for IPF; competing directly for the same patient population with a reformulation strategy and overlapping Phase 2/3 timing.
Broad incumbents
- Galapagos NV: European biopharma with historical IPF pipeline (ziritaxestat failed, but retained fibrosis interests); relevant broad peer given European footprint and inflammation/fibrosis focus.
- United Therapeutics: Markets Tyvaso, an approved therapy used in PH-ILD and related fibrotic lung indications; a competing commercial player in the broader fibrotic lung disease space.
- Boehringer Ingelheim (Ofev franchise): Markets Ofev (nintedanib), the leading approved IPF therapy; defines the efficacy and safety benchmark any new entrant such as CAL101 must beat or match.
- Roche (Esbriet franchise): Sold Esbriet (pirfenidone), the other approved IPF therapy and historical standard of care; relevant as the established benchmark Calluna's S100A4 mechanism must outperform.
Emerging players
- Vicore Pharma: Swedish clinical-stage biotech developing buloxibutid (C21) for IPF; European geographic peer with similar clinical-stage positioning and IPF lead indication.
- Blade Therapeutics: Clinical-stage biotech developing calpain inhibitors for IPF and other fibrotic diseases; smaller peer with overlapping fibrosis indications and similar development stage.
- Endeavor BioMedicines: Clinical-stage biotech developing ENV-101 (taladegib) for IPF; competing in the same Phase 2 IPF indication with a Hedgehog pathway mechanism.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Calluna Pharma social profiles
Digital presenceCalluna Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Calluna Pharma leadership team
Management profileNumber of profiles
Profiles5 records
Calluna Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Calluna Pharma M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Calluna Pharma
What does Calluna Pharma do?
Calluna Pharma is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers (the DAMP protein S100A4 and oxidized phospholipids) to treat chronic inflammatory and fibrotic diseases. Its lead candidate CAL101 is in Phase 2 development for idiopathic pulmonary fibrosis (IPF), while CAL103 is being co-developed with Lilly ExploR&D for chronic inflammatory indications such as COPD and rheumatoid arthritis.
Is Calluna Pharma a public or private company?
Calluna Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Calluna Pharma founded?
Calluna Pharma was founded in 2023. It employs 11 to 50 people.
Where is Calluna Pharma based?
Calluna Pharma is headquartered in Oslo, Norway, in the Europe region.
How does Calluna Pharma make money?
One revenue line is on record: pharmaceutical Drug Development & Licensing.
Who are Calluna Pharma's main competitors?
Direct peers on record are FibroGen, Pliant Therapeutics and Avalyn Pharma. Broad incumbents are Galapagos NV, United Therapeutics, Boehringer Ingelheim (Ofev franchise) and Roche (Esbriet franchise). Emerging players are Vicore Pharma, Blade Therapeutics and Endeavor BioMedicines.
Does Calluna Pharma have an API?
No public API is recorded for Calluna Pharma.
What industry is Calluna Pharma in?
Calluna Pharma's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.